Logo image of HLN

HALEON PLC-ADR (HLN) Stock Fundamental Analysis

NYSE:HLN - New York Stock Exchange, Inc. - US4055521003 - ADR - Currency: USD

11.09  +0.07 (+0.64%)

Fundamental Rating

5

Taking everything into account, HLN scores 5 out of 10 in our fundamental rating. HLN was compared to 198 industry peers in the Pharmaceuticals industry. While HLN has a great profitability rating, there are some minor concerns on its financial health. HLN has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year HLN was profitable.
HLN had a positive operating cash flow in the past year.
Each year in the past 5 years HLN has been profitable.
Each year in the past 5 years HLN had a positive operating cash flow.
HLN Yearly Net Income VS EBIT VS OCF VS FCFHLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

1.2 Ratios

HLN has a better Return On Assets (4.20%) than 86.87% of its industry peers.
HLN has a Return On Equity of 8.92%. This is amongst the best in the industry. HLN outperforms 86.87% of its industry peers.
HLN has a better Return On Invested Capital (6.11%) than 83.84% of its industry peers.
HLN had an Average Return On Invested Capital over the past 3 years of 6.15%. This is significantly below the industry average of 42.34%.
Industry RankSector Rank
ROA 4.2%
ROE 8.92%
ROIC 6.11%
ROA(3y)3.44%
ROA(5y)3.54%
ROE(3y)7.24%
ROE(5y)6.28%
ROIC(3y)6.15%
ROIC(5y)5.77%
HLN Yearly ROA, ROE, ROICHLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2 4 6 8

1.3 Margins

HLN's Profit Margin of 12.84% is amongst the best of the industry. HLN outperforms 89.39% of its industry peers.
In the last couple of years the Profit Margin of HLN has grown nicely.
The Operating Margin of HLN (21.31%) is better than 86.87% of its industry peers.
HLN's Operating Margin has improved in the last couple of years.
HLN has a better Gross Margin (60.75%) than 68.69% of its industry peers.
In the last couple of years the Gross Margin of HLN has remained more or less at the same level.
Industry RankSector Rank
OM 21.31%
PM (TTM) 12.84%
GM 60.75%
OM growth 3Y-0.45%
OM growth 5Y3.75%
PM growth 3Y-4.12%
PM growth 5Y10.69%
GM growth 3Y0.43%
GM growth 5Y0.58%
HLN Yearly Profit, Operating, Gross MarginsHLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

4

2. Health

2.1 Basic Checks

HLN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for HLN has been reduced compared to 1 year ago.
HLN has less shares outstanding than it did 5 years ago.
HLN has a worse debt/assets ratio than last year.
HLN Yearly Shares OutstandingHLN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B
HLN Yearly Total Debt VS Total AssetsHLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

HLN has an Altman-Z score of 2.44. This is not the best score and indicates that HLN is in the grey zone with still only limited risk for bankruptcy at the moment.
HLN's Altman-Z score of 2.44 is fine compared to the rest of the industry. HLN outperforms 71.72% of its industry peers.
The Debt to FCF ratio of HLN is 5.11, which is a neutral value as it means it would take HLN, 5.11 years of fcf income to pay off all of its debts.
HLN has a better Debt to FCF ratio (5.11) than 83.84% of its industry peers.
HLN has a Debt/Equity ratio of 0.53. This is a neutral value indicating HLN is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.53, HLN is doing worse than 61.11% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF 5.11
Altman-Z 2.44
ROIC/WACC0.78
WACC7.85%
HLN Yearly LT Debt VS Equity VS FCFHLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.3 Liquidity

A Current Ratio of 0.98 indicates that HLN may have some problems paying its short term obligations.
With a Current ratio value of 0.98, HLN is not doing good in the industry: 82.83% of the companies in the same industry are doing better.
A Quick Ratio of 0.78 indicates that HLN may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.78, HLN is doing worse than 83.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.78
HLN Yearly Current Assets VS Current LiabilitesHLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

4

3. Growth

3.1 Past

HLN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.59%.
Measured over the past years, HLN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 17.56% on average per year.
The Revenue has decreased by -0.61% in the past year.
Measured over the past years, HLN shows a small growth in Revenue. The Revenue has been growing by 5.78% on average per year.
EPS 1Y (TTM)6.59%
EPS 3Y1.58%
EPS 5Y17.56%
EPS Q2Q%32.07%
Revenue 1Y (TTM)-0.61%
Revenue growth 3Y5.58%
Revenue growth 5Y5.78%
Sales Q2Q%-0.25%

3.2 Future

The Earnings Per Share is expected to grow by 13.19% on average over the next years. This is quite good.
Based on estimates for the next years, HLN will show a small growth in Revenue. The Revenue will grow by 3.80% on average per year.
EPS Next Y9.06%
EPS Next 2Y8.99%
EPS Next 3Y8.81%
EPS Next 5Y13.19%
Revenue Next Year0.74%
Revenue Next 2Y2.54%
Revenue Next 3Y3.21%
Revenue Next 5Y3.8%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
HLN Yearly Revenue VS EstimatesHLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
HLN Yearly EPS VS EstimatesHLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 0.2 0.4 0.6

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 22.63, which indicates a rather expensive current valuation of HLN.
Compared to the rest of the industry, the Price/Earnings ratio of HLN indicates a rather cheap valuation: HLN is cheaper than 82.32% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of HLN to the average of the S&P500 Index (26.60), we can say HLN is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 20.90, the valuation of HLN can be described as rather expensive.
HLN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. HLN is cheaper than 76.77% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of HLN to the average of the S&P500 Index (22.43), we can say HLN is valued inline with the index average.
Industry RankSector Rank
PE 22.63
Fwd PE 20.9
HLN Price Earnings VS Forward Price EarningsHLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HLN indicates a rather cheap valuation: HLN is cheaper than 80.30% of the companies listed in the same industry.
HLN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HLN is cheaper than 84.34% of the companies in the same industry.
Industry RankSector Rank
P/FCF 18.88
EV/EBITDA 16.59
HLN Per share dataHLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
HLN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.5
PEG (5Y)1.29
EPS Next 2Y8.99%
EPS Next 3Y8.81%

More info and screens

3

5. Dividend

5.1 Amount

HLN has a Yearly Dividend Yield of 1.64%.
HLN's Dividend Yield is rather good when compared to the industry average which is at 4.24. HLN pays more dividend than 91.41% of the companies in the same industry.
Compared to the average S&P500 Dividend Yield of 2.36, HLN is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.64%

5.2 History

HLN has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of HLN decreased recently.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
HLN Yearly Dividends per shareHLN Yearly Dividends per shareYearly Dividends per share 2023 2024 2025 0.01 0.02 0.03 0.04 0.05

5.3 Sustainability

DPN/A
EPS Next 2Y8.99%
EPS Next 3Y8.81%
HLN Yearly Income VS Free CF VS DividendHLN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

HALEON PLC-ADR

NYSE:HLN (5/21/2025, 3:59:00 PM)

11.09

+0.07 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-30 2025-04-30
Earnings (Next)N/A N/A
Inst Owners49.58%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap50.01B
Analysts77.6
Price Target11.47 (3.43%)
Short Float %0.5%
Short Ratio1.68
Dividend
Industry RankSector Rank
Dividend Yield 1.64%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years1
Div Non Decr Years1
Ex-Date04-24 2025-04-24 (0.046)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.58%
Min EPS beat(2)-1.92%
Max EPS beat(2)7.08%
EPS beat(4)3
Avg EPS beat(4)3.76%
Min EPS beat(4)-1.92%
Max EPS beat(4)7.54%
EPS beat(8)4
Avg EPS beat(8)-10.37%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.51%
Min Revenue beat(2)-5.38%
Max Revenue beat(2)-1.64%
Revenue beat(4)0
Avg Revenue beat(4)-3.11%
Min Revenue beat(4)-5.38%
Max Revenue beat(4)-1.64%
Revenue beat(8)1
Avg Revenue beat(8)-2.55%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.97%
PT rev (3m)7.89%
EPS NQ rev (1m)0.07%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.07%
EPS NY rev (3m)-1.08%
Revenue NQ rev (1m)0.2%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.92%
Revenue NY rev (3m)-2.28%
Valuation
Industry RankSector Rank
PE 22.63
Fwd PE 20.9
P/S 3.33
P/FCF 18.88
P/OCF 16.27
P/B 2.32
P/tB N/A
EV/EBITDA 16.59
EPS(TTM)0.49
EY4.42%
EPS(NY)0.53
Fwd EY4.78%
FCF(TTM)0.59
FCFY5.3%
OCF(TTM)0.68
OCFY6.14%
SpS3.33
BVpS4.79
TBVpS-2.97
PEG (NY)2.5
PEG (5Y)1.29
Profitability
Industry RankSector Rank
ROA 4.2%
ROE 8.92%
ROCE 8.4%
ROIC 6.11%
ROICexc 6.63%
ROICexgc 4145.85%
OM 21.31%
PM (TTM) 12.84%
GM 60.75%
FCFM 17.65%
ROA(3y)3.44%
ROA(5y)3.54%
ROE(3y)7.24%
ROE(5y)6.28%
ROIC(3y)6.15%
ROIC(5y)5.77%
ROICexc(3y)6.57%
ROICexc(5y)6.04%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)8.5%
ROCE(5y)8.01%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y12.56%
ROICexc growth 5Y14.99%
OM growth 3Y-0.45%
OM growth 5Y3.75%
PM growth 3Y-4.12%
PM growth 5Y10.69%
GM growth 3Y0.43%
GM growth 5Y0.58%
F-Score6
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF 5.11
Debt/EBITDA 3.18
Cap/Depr 98.15%
Cap/Sales 2.83%
Interest Coverage 6.65
Cash Conversion 84.66%
Profit Quality 137.52%
Current Ratio 0.98
Quick Ratio 0.78
Altman-Z 2.44
F-Score6
WACC7.85%
ROIC/WACC0.78
Cap/Depr(3y)107.06%
Cap/Depr(5y)107.33%
Cap/Sales(3y)2.94%
Cap/Sales(5y)3.03%
Profit Quality(3y)156.45%
Profit Quality(5y)128.12%
High Growth Momentum
Growth
EPS 1Y (TTM)6.59%
EPS 3Y1.58%
EPS 5Y17.56%
EPS Q2Q%32.07%
EPS Next Y9.06%
EPS Next 2Y8.99%
EPS Next 3Y8.81%
EPS Next 5Y13.19%
Revenue 1Y (TTM)-0.61%
Revenue growth 3Y5.58%
Revenue growth 5Y5.78%
Sales Q2Q%-0.25%
Revenue Next Year0.74%
Revenue Next 2Y2.54%
Revenue Next 3Y3.21%
Revenue Next 5Y3.8%
EBIT growth 1Y4.68%
EBIT growth 3Y5.1%
EBIT growth 5Y9.75%
EBIT Next Year15.06%
EBIT Next 3Y9.08%
EBIT Next 5Y10.44%
FCF growth 1Y12.42%
FCF growth 3Y23.3%
FCF growth 5Y29.57%
OCF growth 1Y9.57%
OCF growth 3Y19.28%
OCF growth 5Y23.96%